GlassScriptPhysician profile
Latoya Carpenter
NPI 1639765027
$2,525.04
in general payments reported to CMS, 2019-2025
24 companies · $1,157 in 2025
The $1,157 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $217 · 2022: $414 · 2023: $162 · 2024: $574 · 2025: $1,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,893.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $332.15 | 2025 | Wegovy, Rybelsus, Ozempic |
| Teva Pharmaceuticals USA, INC. | $238.99 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $215.27 | 2024-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $213.27 | 2023-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $183.99 | 2024-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $168.12 | 2022-2025 | Intellis Adaptivestim |
| Abbvie INC. | $124.99 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $123.84 | 2022 | |
| Sanofi-Aventis U.S. LLC | $121.85 | 2024 | |
| Abiomed | $104.17 | 2024 | Impella |
| Glaxosmithkline, LLC. | $97.03 | 2024-2025 | Shingrix, Arexvy |
| Genzyme Corporation | $93.80 | 2021 | |
| Dexcom, INC. | $82.82 | 2024 | Dexcom G7 Gss (161) |
| Amgen INC. | $64.24 | 2025 | Repatha |
| Boston Scientific Corporation | $59.28 | 2023-2025 | Watchman Access System |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $57.85 | 2025 | |
| Abbott Laboratories | $52.13 | 2024-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.27 | 2024-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $40.78 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.55 | 2025 | |
| Gilead Sciences, INC. | $21.04 | 2025 | |
| Merck Sharp & Dohme LLC | $20.21 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Astellas Pharma US INC | $20.21 | 2025 | Veozah |
| Lucid Diagnostics INC. | $16.19 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Latoya Carpenter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.